{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T11:41:55Z","timestamp":1790854915940,"version":"4.1.0"},"reference-count":28,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2021,3,25]],"date-time":"2021-03-25T00:00:00Z","timestamp":1616630400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Basic Clin Pharma Tox"],"published-print":{"date-parts":[[2021,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Few studies have evaluated the influence of valproate on the deterioration of the lipid profile in psychiatric patients. This observational study aimed to compare the evolution of metabolic parameters in a sample of adult patients starting valproate (n\u00a0=\u00a039) with a control group (n\u00a0=\u00a039) of patients starting aripiprazole, a drug associated with a low risk of metabolic deterioration. Data were obtained from a prospective study including psychiatric patients with metabolic parameters monitored during the first year of treatment. During the first month of treatment with valproate (median: 31\u00a0days [IQR: 25\u201036]), mean body mass index increased significantly (from 24.8\u00a0kg\/m<jats:sup>2<\/jats:sup> at baseline to 25.2\u00a0kg\/m<jats:sup>2<\/jats:sup> after one month; <jats:italic>P\u00a0<\/jats:italic>=\u00a0.03) and mean HDL\u2010C levels decreased significantly (from 1.39\u00a0mmol\/L to 1.27\u00a0mmol\/L; <jats:italic>P\u00a0<\/jats:italic>=\u00a0.02). In comparison, these metabolic variables remained stable during the first month of treatment with aripiprazole. The proportion of patients with early (ie during the first month of treatment) HDL\u2010C decrease of \u2265\u00a05% was significantly higher under valproate (54%) than aripiprazole (15%) treatment (<jats:italic>P\u00a0<\/jats:italic>&lt;\u00a0.001). These findings remind the importance of a prospective metabolic monitoring in patients who initiate valproate treatment. Further research should be conducted on larger samples and should focus on finding effective interventions to prevent such metabolic adverse effects.<\/jats:p>","DOI":"10.1111\/bcpt.13580","type":"journal-article","created":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T08:12:38Z","timestamp":1616055158000},"page":"26-35","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Valproate is associated with early decrease of high\u2010density lipoprotein cholesterol levels in the psychiatric population"],"prefix":"10.1111","volume":"129","author":[{"given":"Aur\u00e9lie","family":"Delacr\u00e9taz","sequence":"first","affiliation":[{"name":"Department of Psychiatry Unit of Pharmacogenetics and Clinical Psychopharmacology Centre for Psychiatric Neuroscience Lausanne University Hospital University of Lausanne Prilly Switzerland"},{"name":"Les Toises Psychiatry and Psychotherapy Center Lausanne Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana\u00efs","family":"Glatard","sequence":"additional","affiliation":[{"name":"Department of Psychiatry Unit of Pharmacogenetics and Clinical Psychopharmacology Centre for Psychiatric Neuroscience Lausanne University Hospital University of Lausanne Prilly Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Dubath","sequence":"additional","affiliation":[{"name":"Department of Psychiatry Unit of Pharmacogenetics and Clinical Psychopharmacology Centre for Psychiatric Neuroscience Lausanne University Hospital University of Lausanne Prilly Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Gholam","sequence":"additional","affiliation":[{"name":"Department of Psychiatry Centre of Psychiatric Epidemiology and Psychopathology Lausanne University Hospital University of Lausanne Lausanne Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franziska","family":"Gamma","sequence":"additional","affiliation":[{"name":"Les Toises Psychiatry and Psychotherapy Center Lausanne Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armin","family":"von Gunten","sequence":"additional","affiliation":[{"name":"Department of Psychiatry Service of Old Age Psychiatry Lausanne University Hospital University of Lausanne Lausanne Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Conus","sequence":"additional","affiliation":[{"name":"Department of Psychiatry Service of General Psychiatry Lausanne University Hospital University of Lausanne Lausanne Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5439-0230","authenticated-orcid":false,"given":"Chin B.","family":"Eap","sequence":"additional","affiliation":[{"name":"Department of Psychiatry Unit of Pharmacogenetics and Clinical Psychopharmacology Centre for Psychiatric Neuroscience Lausanne University Hospital University of Lausanne Prilly Switzerland"},{"name":"Center for Research and Innovation in Clinical Pharmaceutical Sciences Lausanne University Hospital and University of Lausanne Lausanne Switzerland"},{"name":"School of Pharmaceutical Sciences University of Geneva Geneva Switzerland"},{"name":"Institute of Pharmaceutical Sciences of Western Switzerland University of Geneva Geneva Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,3,25]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(17)30078-0"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2014.2502"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2011.156"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/wps.20204"},{"issue":"171","key":"e_1_2_9_6_1","first-page":"1994","article-title":"Follow\u2010up of the metabolic syndrome induced by atypical antipsychotics: recommendations and pharmacogenetics perspectives","volume":"4","author":"Choong E","year":"2008","journal-title":"Rev Med Suisse."},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2017.10.002"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00208485"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2014.05.011"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2015.03.002"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2017.03.007"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychires.2013.06.017"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60733-3"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(19)30416-X"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881116645254"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2013.187"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.hjh.0000431740.32696.cc"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10903-015-0320-z"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0094112"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2007.02.024"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/wps.20252"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.14m09358"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-244X-13-138"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-014-3453-1"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1186\/2194-7511-1-10"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S50248"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1097\/HJR.0b013e32832c8891"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.79.1.8"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1467-789X.2010.00800.x"}],"container-title":["Basic &amp; Clinical Pharmacology &amp; Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcpt.13580","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bcpt.13580","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcpt.13580","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,30]],"date-time":"2023-08-30T16:41:05Z","timestamp":1693413665000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bcpt.13580"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,25]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["10.1111\/bcpt.13580"],"URL":"https:\/\/doi.org\/10.1111\/bcpt.13580","archive":["Portico"],"relation":{},"ISSN":["1742-7835","1742-7843"],"issn-type":[{"value":"1742-7835","type":"print"},{"value":"1742-7843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,25]]},"assertion":[{"value":"2020-09-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-03-09","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-03-25","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}